David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

In patients with COPD and atrial fibrillation or flutter, vitamin K antagonists carry a lower 1‑year risk for hospitalization ...

Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA). Jeffrey D.

COPD, or chronic obstructive pulmonary disease, is a group of life-changing lung diseases that include emphysema and chronic bronchitis. 1 Those living with COPD can experience coughing, wheezing, ...

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

Triple therapy in COPD significantly improves lung function vs LAMA monotherapy, LABA/LAMA, and ICS/LABA, although evidence showing this is often low quality. Triple therapy is likely effective, safe, ...

Effective treatment often requires you to take medications to better manage symptoms or stop taking medications if a doctor advises that you no longer need them. Finding the right dosages and ...

Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...